Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kennedy, J. M.
Right arrow Articles by Zochodne, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennedy, J. M.
Right arrow Articles by Zochodne, D. W.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:830-837, 2005
© 2005 by the American Diabetes Association, Inc.

Experimental Diabetic Neuropathy With Spontaneous Recovery

Is There Irreparable Damage?

James M. Kennedy, and Douglas W. Zochodne

From the Department of Clinical Neurosciences and the Neuroscience Research Group, University Of Calgary, Calgary, Alberta, Canada

Progressive diabetic neuropathy has hitherto been irreversible in humans. New approaches raise the question of whether islet cell reconstitution rendering euglycemia can reverse specific features of neuropathy. We evaluated physiological and structural features of experimental neuropathy in a long-term murine model of diabetes induced by streptozotocin. By serendipity, a subset of these diabetic mice spontaneously regained islet function and attained near-euglycemia. Our hypotheses were that this model might better reflect axon loss observed in human disease and that spontaneous recovery from diabetes might identify the features of neuropathy that are reversible. In this model, experimental neuropathy closely modeled that in humans in most critical aspects: declines in motor conduction velocities, attenuation of compound muscle (M waves) and nerve action potentials, axon atrophy, myelin thinning, loss of epidermal axons, and loss of sweat gland innervation. Overt sensory neuron loss in dorsal root ganglia was a feature of this model. In mice with recovery, there was robust electrophysiological improvement, less myelin thinning, and remarkable epidermal and sweat gland reinnervation. There was, however, no recovery of populations of lost sensory neurons. Our findings identify a robust model of human diabetic neuropathy and indicate that overt, irretrievable loss of sensory neurons is one of its features, despite collateral reinnervation of target organs. Sensory neurons deserve unique protective strategies irrespective of islet cell reconstitution.


Address correspondence and reprint requests to Dr. D.W. Zochodne, University of Calgary, 3330 Hospital Dr. NW, Calgary, Alberta T2N 4N1, Canada. E-mail: dzochodn{at}ucalgary.ca


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
V. Brussee, G. Guo, Y. Dong, C. Cheng, J. A. Martinez, D. Smith, G. W. Glazner, P. Fernyhough, and D. W. Zochodne
Distal Degenerative Sensory Neuropathy in a Long-Term Type 2 Diabetes Rat Model
Diabetes, June 1, 2008; 57(6): 1664 - 1673.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Toth, L. L. Rong, C. Yang, J. Martinez, F. Song, N. Ramji, V. Brussee, W. Liu, J. Durand, M. D. Nguyen, et al.
Receptor for Advanced Glycation End Products (RAGEs) and Experimental Diabetic Neuropathy
Diabetes, April 1, 2008; 57(4): 1002 - 1017.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. G. Smith, J. Russell, E. L. Feldman, J. Goldstein, A. Peltier, S. Smith, J. Hamwi, D. Pollari, B. Bixby, J. Howard, et al.
Lifestyle Intervention for Pre-Diabetic Neuropathy.
Diabetes Care, June 1, 2006; 29(6): 1294 - 1299.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Demiot, M. Tartas, B. Fromy, P. Abraham, J. L. Saumet, and D. Sigaudo-Roussel
Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy.
Diabetes, May 1, 2006; 55(5): 1478 - 1483.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y. S. Chen, S. S.M. Chung, and S. K. Chung
Noninvasive Monitoring of Diabetes-Induced Cutaneous Nerve Fiber Loss and Hypoalgesia in thy1-YFP Transgenic Mice
Diabetes, November 1, 2005; 54(11): 3112 - 3118.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.